Recurrent Cervical Cancer Clinical Trial
Verified date | July 2018 |
Source | Fuda Cancer Hospital, Guangzhou |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent cervical cancer.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 1, 2019 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 30 Years to 70 Years |
Eligibility |
Inclusion Criteria: - All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence - Body tumor 1-6, the maximum tumor length < 5 cm - KPS = 70, lifespan > 6 months - Platelet count = 80×109/L,white blood cell count = 3×109/L, neutrophil count = 2×109/L, hemoglobin = 80 g/L Exclusion Criteria: - Patients with cardiac pacemaker - Patients with brain metastasis - Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction |
Country | Name | City | State |
---|---|---|---|
China | Fuda cancer institute of Fuda cancer hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Fuda Cancer Hospital, Guangzhou | Shenzhen Hank Bioengineering Institute |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relief degree of tumors | It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST) | 3 months | |
Secondary | Progress free survival(PFS) | 1 year | ||
Secondary | Overall survival(OS) | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01764789 -
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
|
N/A | |
Active, not recruiting |
NCT04341883 -
Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer
|
Phase 2 | |
Completed |
NCT01652794 -
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
|
Phase 1 | |
Completed |
NCT01079832 -
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
|
Phase 2 | |
Completed |
NCT00335998 -
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
|
Phase 1 | |
Completed |
NCT00031993 -
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
|
Phase 2 | |
Completed |
NCT01155258 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04974944 -
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
|
Phase 2 | |
Completed |
NCT00941070 -
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
|
Phase 2 | |
Completed |
NCT04380805 -
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
|
Phase 2 | |
Completed |
NCT00389974 -
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00030498 -
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
|
Phase 1 | |
Completed |
NCT00031681 -
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
|
Phase 1 | |
Recruiting |
NCT04191226 -
Genetic Mutation in Recurrent Cervical Cancer
|
||
Completed |
NCT01676818 -
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
|
Phase 2 | |
Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 | |
Completed |
NCT00025233 -
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
|
Phase 2 | |
Terminated |
NCT04230954 -
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
|
Phase 2 | |
Withdrawn |
NCT01313104 -
Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer
|
N/A |